Loading..

Vaxart, Inc. (VXRT) Report Analysis

Corporate Events

Neutral

Vaxart, Inc. - Shareholder/Analyst Call

2022-06-16 20:07:00

To provide an overview of the Company’s oral vaccine programs

Positive

Vaxart, Inc. Presents New Preclinical Data Demo...

2022-06-03 12:00:00

Vaxart, Inc. reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2...

Positive

Vaxart Reports Positive Preliminary Data from t...

2022-06-02 12:30:00

Vaxart reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 ye...

Neutral

Vaxart, Inc. Presents at 2022 Jefferies Global ...

2022-06-02 12:00:00

Vaxart, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:30 AM. Venue: Marriott Marquis, New York City, New York, ...

Positive

Vaxart Announces the Publication of Studies in ...

2022-05-19 12:30:00

Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2. The report also described updated res...

Negative

Vaxart, Inc. Announces CFO Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), a chief financial officer ...

Negative

Vaxart, Inc. Announces Management Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), in his capacity as a non-e...

Neutral

Vaxart, Inc. Proposes Amendment to Restated Cer...

2022-04-28 20:04:00

Vaxart, Inc. proposed amendment to Restated Certificate of Incorporation to increase the authorized number of shares of common stock to 250,00...

Neutral

Vaxart, Inc. Presents at World Vaccine Congress...

2022-04-16 13:52:00

Vaxart, Inc. Presents at World Vaccine Congress 2022, Apr-20-2022 03:55 PM. Venue: Marriott Marquis Washington, Washington , District Of Colum...

Negative

Margaret Echerd Notifies as Senior Vice Preside...

2022-03-31 20:12:00

On March 28, 2022, Margaret Echerd notified Vaxart, Inc. that she intends to retire as Senior Vice President and Principal Accounting Officer,...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Terrapinn Holdings Ltd, World Vaccine Congress ...

2022-01-27 09:13:00

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022. Venue: Marriott Marquis Washington, Washington , Distr...

Positive

Vaxart to Test Cross-Reactivity of Its Covid-19...

2021-12-16 13:00:00

Vaxart, Inc. said it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant i...

Positive

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBi...

2021-12-01 00:00:00

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Bioscienc...

Neutral

Vaxart, Inc. Presents at Piper Sandler 33rd Ann...

2021-11-22 15:06:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Stanford Scientists First To Identify New Cellu...

2021-11-18 21:02:00

A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under devel...

Positive

Vaxart, Inc. Announces Publication of Complete ...

2021-11-16 13:00:00

Vaxart, Inc. announced the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The s...

Neutral

Vaxart, Inc. Presents at 12th Annual Jefferies ...

2021-11-11 21:01:00

Vaxart, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Ce...

Neutral

Vaxart, Inc. Presents at Piper Sandler 33rd Ann...

2021-11-11 21:01:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Cezar Andrei ...

Positive

Vaxart Doses First Subject in Phase II COVID-19...

2021-10-26 12:00:00

Vaxart, Inc. announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II tria...

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Positive

Vaxart, Inc. Recruiting in Global Phase II COVI...

2021-10-06 12:00:00

Vaxart, Inc. announced?that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial. Vaxart expects to b...

Negative

Vaxart, Inc Appoints James F. Cummings as Chief...

2021-09-27 12:00:00

Vaxart, Inc. announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certi...

Neutral

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2...

2021-09-22 20:05:00

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2021 through Oct 06, 2021.

Neutral

Vaxart, Inc. Presents at 15th Vaccine Congress,...

2021-09-22 20:05:00

Vaxart, Inc. Presents at 15th Vaccine Congress, Oct-05-2021 06:00 AM. Speakers: Susan Johnson, senior scientists.

Neutral

Vaxart, Inc. Presents at Cantor Global Healthca...

2021-09-22 17:33:00

Vaxart, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 10:40 AM. Venue: New York, United States. Speakers: Cezar Andre...

Positive

Vaxart, Inc. Enters into A Lease Agreement with...

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into a lease agreement with Britannia Pointe Grand Limited Partnership, a Delaware limited partner...

Positive

Vaxart, Inc. Enters into the Second Amendment t...

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporat...

Negative

Vaxart, Inc. Announces Board Appointments

2021-09-21 20:15:00

Vaxart, Inc. announced that it has formed a Manufacturing and Quality Advisory Board. The six leaders joining Vaxart's COVID-19 Manufacturing ...

Negative

Vaxart, Inc. has filed a Follow-on Equity Offer...

2021-09-16 00:00:00

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock ...

Negative

Vaxart, Inc. has completed a Follow-on Equity O...

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common ...

Negative

Vaxart, Inc. has completed a Follow-on Equity O...

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common ...

Neutral

Vaxart, Inc. Presents at H.C. Wainwright 23rd A...

2021-09-07 20:20:00

Vaxart, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, N...

Negative

Vaxart, Inc. Appoints Julie M. Cherrington to t...

2021-08-23 20:23:00

On August 20, 2021, the Board of Directors of Vaxart, Inc. appointed Julie M. Cherrington, Ph.D., to serve on the Board until her successor is...

Negative

Vaxart, Inc. Announces the Creation of an Eight...

2021-08-19 20:02:00

Vaxart, Inc. announced the creation of an eight-member Scientific and Clinical Advisory Board. The Advisory Board, whose first meeting occurre...

Neutral

Vaxart, Inc. Presents at World Vaccine & Immuno...

2021-08-18 15:33:00

Vaxart, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:40 PM. Venue: Loews Coronado Bay Resort, San D...

Positive

Vaxart, Inc. Announces FDA Clearance IND Applic...

2021-08-02 12:00:00

Vaxart, Inc. announced that the U.S. Food and Drug Administration has cleared Vaxart's Investigational New Drug application for an S-only oral...

Positive

Vaxart, Inc. Reports Boosting Immune Responses ...

2021-07-29 12:22:00

Vaxart, Inc. announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immu...

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunot...

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay R...

Negative

Vaxart, Inc. Announces Auditor Changes

2021-07-20 10:05:00

On July 15, 2021, Vaxart, Inc. was notified that OUM & Co. LLP, an independent registered public accounting firm, had combined its practice wi...

Neutral

Vaxart Announces Exclusive Worldwide License Ag...

2021-07-07 12:00:00

Vaxart, Inc. announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allow Altesa to develop ...

Neutral

Vaxart, Inc. - Shareholder/Analyst Call

2022-06-16 20:07:00

To provide an overview of the Company’s oral vaccine programs

Positive

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

2022-06-03 12:00:00

Vaxart, Inc. reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant. "Approved COVID-19 vaccines afford less protection against infection from new SARS-CoV-2 variants compared with the original parental strain against which they were developed. A broadly cross-reactive vaccine may be the most effective way to protect against current and future variants. The data reported are from a study in which the S-only Wuhan and Omicron vaccine candidates were compared in a hamster challenge model. Animals were immunized mucosally on days zero and 28 and challenged on day 56 with an Omicron varia of SARS-CoV-2-2. Both vaccines produced antibody responses to the S protein of Omicron, with the Omicron candidate slightly better at making serum IgG antibodies to the matched protein. Weight loss, lung viral titers, and viral shedding were reduced in animals receiving either vaccine candidate compared to unvaccinated animals. These findings demonstrate that in this preclinical model both vaccine candidates protect against the Omicron variant.t. Earlier this year, Vaxart announced that data from its non-human primate study showed that the S-only candidate generated antibodies to the original COVID-19 Wuhan strain and those antibodies also react strongly with the Beta, Delta, Alpha and Gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates.

Positive

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

2022-06-02 12:30:00

Vaxart reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 years (NCT04854746). Results of the trial show a robust immune response across all doses, with a dose-dependent production of IgA antibody secreting cells (ASCs), consistent with previous studies conducted in younger populations. The results also demonstrate that the vaccine candidate was well tolerated with a favorable safety profile. These data support the continued development of Vaxart’s oral norovirus vaccine candidate in adult populations, including elderly adults, and add to the growing body of evidence supporting its clinical utility. Vaxart is conducting a Phase 2 clinical challenge study of its norovirus vaccine candidate in adult volunteers. Norovirus is the leading cause of acute gastroenteritis that produces vomiting and diarrhea among people of all ages. The World Health Organization’s (WHO) Product Development for Vaccines Advisory Committee has identified norovirus as a priority disease for vaccine development. The virus causes up to 21 million cases, 109,000 hospitalizations and 900 deaths annually in the United States. Adults over the age of 65 years are especially vulnerable to norovirus infection, with 7.5% of this population infected annually. Norovirus also has a negative health economic impact, which has been estimated to cost $10.6 billion annually in the United States alone. Key findings from the Phase 1b study in elderly patients include: Robust immune response across all doses, with a dose dependent IgA ASC response IgA ASC responses were consistent with previous studies in younger subjects All solicited adverse events were mild or moderate with generally similar rates of events between the vaccine groups and placebo Vaxart is also reporting preliminary data from a Phase 1 boosting regimen of its norovirus vaccine candidate. These data show that the candidate was able to successfully boost antibody responses, with antibody responses trending better with administration spread out over 3 months versus a shorter interval. Vaxart has previously reported that booster administration at a year post first dose was able to return antibody titers to levels similar to what was observed after the first dose.

Neutral

Vaxart, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:30 AM

2022-06-02 12:00:00

Vaxart, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:30 AM. Venue: Marriott Marquis, New York City, New York, United States.

Positive

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

2022-05-19 12:30:00

Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2. The report also described updated results from Vaxart’s Phase I clinical trial that suggest Vaxart’s other vaccine candidate, the one targeting both the S and N proteins, could be effective against a range of diverse coronaviruses. The study compared various measures of immunity and viral shedding in hamster cohorts immunized with Vaxart’s S-only vaccine candidate (administered orally and intranasally), an intramuscular protein vaccine control and placebo. The vaccinated hamsters were then infected with high doses of SARS-CoV-2 to create vaccine breakthrough and exposed to naïve animals during the breakthrough period. The study authors concluded that Vaxart’s S-only construct “reduced disease and decreased airborne transmission in a hamster model.” The publication also reported results from the Phase I clinical study of Vaxart’s S+N vaccine candidate showing that it stimulated SARS-CoV-2-specific IgA antibodies in saliva and nasal samples from human subjects and was cross-reactive to many different coronaviruses that are more divergent than circulating variants of SARS-CoV-2. The S-only data from the hamster transmission preclinical study was initially reported last October in the non-peer reviewed journal bioRxiv. Vaxart first reported the potential cross-reactive properties of its S+N vaccine candidate in May 2021. The new Science Translational Medicine publication includes additional detail regarding IgA antibody responses in human subjects. Vaxart has moved to Phase II clinical trials with the S-only vaccine candidate and expects to report those results later this year. Vaxart has also completed and published preliminary Phase I results from its S+N vaccine candidate. As previously stated, the company plans to compare the S-only and S+N vaccine candidates and to decide which approach offers the best way forward for its COVID-19 vaccine development program, particularly in the face of emerging variant strains.

Negative

Vaxart, Inc. Announces CFO Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), a chief financial officer services and board advisory consulting firm, as the Company’s Interim Chief Financial Officer and, in his capacity as a non-employee consultant, as the Company’s Principal Financial Officer while Vaxart conducts its ongoing search for a Chief Financial Officer. As of May 10, 2022, Andrei Floroiu ceased to serve as the Company’s Principal Financial Officer and Margaret Echerd ceased to serve as the Company’s Principal Accounting Officer. Mr. Ahmad has served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, since November 2020.

Negative

Vaxart, Inc. Announces Management Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), in his capacity as a non-employee consultant and as the Principal Accounting Officer. As of May 10, 2022, Margaret Echerd ceased to serve as the Company’s Principal Accounting Officer. Mr. Ahmad has served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, since November 2020. As previously disclosed, on March 28, 2022, Ms. Echerd notified Company that she intended to retire as Senior Vice President and Principal Accounting Officer, effective as of May 5, 2022. Subsequently, Ms. Echerd agreed to delay her retirement until May 11, 2022.

Neutral

Vaxart, Inc. Proposes Amendment to Restated Certificate of Incorporation

2022-04-28 20:04:00

Vaxart, Inc. proposed amendment to Restated Certificate of Incorporation to increase the authorized number of shares of common stock to 250,000,000 shares. in its AGM to be held on June 7, 2022.

Neutral

Vaxart, Inc. Presents at World Vaccine Congress 2022, Apr-20-2022 03:55 PM

2022-04-16 13:52:00

Vaxart, Inc. Presents at World Vaccine Congress 2022, Apr-20-2022 03:55 PM. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States. Speakers: Sean N. Tucker, Senior VP & Chief Scientific Officer.

Negative

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

2022-03-31 20:12:00

On March 28, 2022, Margaret Echerd notified Vaxart, Inc. that she intends to retire as Senior Vice President and Principal Accounting Officer, effective as of May 5, 2022.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022

2022-01-27 09:13:00

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States.

Positive

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

2021-12-16 13:00:00

Vaxart, Inc. said it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month. In the second study, Vaxart will conduct an animal Omicron challenge study to assess how its current Phase II COVID-19 vaccine candidate performs in comparison to an Omicron-specific vaccine candidate that Vaxart is developing. Vaxartdeliberately engineered its COVID-19 vaccine candidate to be cross-reactive against emerging variants based on Vaxart scientists’ early recognition of the risk of emerging variants of SARS-CoV-2. In May 2021, the Company announced Phase I clinical test results demonstrating that its vaccine candidate, VXA-CoV2-1, produced broad cross-reactive T cell and IgA responses against other, non-COVID coronaviruses. Injectable vaccines primarily stimulate serum IgG responses, but Vaxart’s COVID-19 vaccine candidate has been shown to trigger mucosal IgA in the nose, mouth and lungs, where SARS-CoV-2 infection occurs. Mucosal IgA antibodies contain four or more antigen-binding sites, while IgG antibodies contain only two.

Positive

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

2021-12-01 00:00:00

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. on November 30, 2021. Vaxart, Inc. (NasdaqCM:VXRT) agreed to the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility. Vaxart expects the facility to be operational for GMP production in Q1 2022. Vaxart, Inc. (NasdaqCM:VXRT) completed the acquisition of KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. on November 30, 2021.

Neutral

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart, Inc

2021-11-18 21:02:00

A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc., had cellular correlates of protection against influenza infection. These cellular correlates were found using mass cytometry analysis of vaccine-elicited cellular immune responses in the peripheral blood of participants in a previously reported Phase II H1N1 challenge study of VXA-A1.1. The U.S. Centers for Disease Control and Prevention (CDC) estimates that, on average, 36,000 people in the U.S. died from the flu in each of the past ten years. It is estimated that 61,000 people in the U.S. died from the flu in the 2017-2018 season – the higher toll in recent years. The 2019-2020 season, which was shorter than normal, resulted in approximately 22,000 U.S. deaths. Globally, the number of annual flu deaths has been estimated to range from nearly 300,000 to more than 600,000. Results of a Phase II human influenza challenge study following vaccination with VXA-A1.1, which was funded by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), have previously been reported.2 Participants in the Phase II study received either VXA-A1.1, an injected quadrivalent, inactivated influenza vaccine (IIV) or a placebo. Participants were challenged with H1N1 influenza virus 90-120 days after vaccination and were monitored for signs and symptoms of infection and viral shedding. Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV. The results suggested that cellular responses rather than neutralizing antibodies may be especially important in the VXA-A1.1 mechanism of protection. The study announced on November 18, 2021 is the first to use mass cytometry to evaluate more than 40 different immune cell parameters in peripheral blood samples collected from 141 participants in the Phase II study. Mass cytometry immune cell profiling was performed on samples collected immediately prior to (day 1) and seven days following (day 8) vaccine administration. Immune profiling tracked levels of multiple cell subsets with similar patterns of markers. The relationship between each subset and virus shedding was determined. Random forest-based machine learning models were used to define high-dimensional cellular correlates between the immune profiling and viral shedding data. Key findings from the study include: Specific B cell and T cell responses contribute to protection from viral shedding with VXA-A1.1 but not with IIV. At day 8, vaccine-elicited subsets of plasmablasts (including a4ß7+, CD62L-, pSTAT5+ cells) and hemagglutinin (HA+)-specific cells significantly correlated with protection from viral shedding after day 90 in participants vaccinated with VXA-A1.1, but not in participants treated with IIV or placebo. At day 8, VXA-A1.1, but not IIV or placebo, elicited subsets of T cells expressing markers (ß7 integrin and CCR9) that are indicative of enhanced homing to mucosal tissue. Random forest models of the VXA-A1.1-treated group could distinguish those individuals who were later protected versus those who remained susceptible to the virus using datasets from both unsupervised clustering approaches and manual gating (p= 0.00001).

Positive

Vaxart, Inc. Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

2021-11-16 13:00:00

Vaxart, Inc. announced the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vaxart’s COVID-19 oral vaccine candidate’s potential efficacy in preventing SARS-CoV-2 infection. The Hamster Challenge Study adds to the significant body of preclinical and clinical evidence Vaxart has amassed during the last two years supporting its belief that Vaxart’s room temperature oral tablet COVID-19 vaccine candidate, can be effective against SARS-CoV-2: A Hamster Transmission Study, conducted by Duke University and published in bioRxiv last month, demonstrated that the COVID-19 vaccine reduced the airborne transmission of SARS-CoV-2 virus in a hamster model. These results are consistent with those from Vaxart's Phase II human flu challenge study, which showed that Vaxart's oral tablet flu vaccine was better at reducing shedding than the injectable flu vaccine comparator. Vaxart’s Phase I results, released earlier this year, showed that the vaccine triggered multiple immune responses against SARS-CoV-2 antigens, including strong T-cell and IgA responses. Vaxart anticipates its Phase II clinical study to provide additional evidence regarding the potential impact and efficacy of the oral tablet COVID-19 vaccine. Initial data from that study is expected in First Quarter 2022. Key findings from the study include: All hamsters that received two doses of the oral vaccine demonstrated protection from COVID-19. Vaccinated hamsters had no significant loss of weight over the five days post challenge, while unvaccinated hamsters lost up to 10% of their body weight. Lung weight, which can be an indirect measure of lung inflammation, was significantly lower in double-vaccinated hamsters compared with unvaccinated animals. Five days post challenge, double-vaccinated hamsters had a greater than 4 log reduction in viral load and had no detectable infectious virus in their lungs.

Neutral

Vaxart, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-11 21:01:00

Vaxart, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, James F. Cummings, Chief Medical Officer, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Neutral

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-11 21:01:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, James F. Cummings, Chief Medical Officer, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Positive

Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

2021-10-26 12:00:00

Vaxart, Inc. announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II trial of an oral tablet COVID-19 vaccine underway in the world. Vaxart expects to enroll 96 subjects at four sites in the United States in the first part of its Phase II trial. The U.S. trial will be followed by an international trial involving a larger pool of subjects. The U.S. portion of the trial will be a randomized open-label dose and age escalation lead-in segment in naïve and previously vaccinated subjects, to be followed by an international placebo-controlled efficacy trial. The full data set from the U.S. trial is expected in First Quarter 2022. Vaxart has recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants in parallel. This allowed the company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials planned to start in 2021, and to start manufacturing vaccines for its upcoming norovirus Phase II trials.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Positive

Vaxart, Inc. Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

2021-10-06 12:00:00

Vaxart, Inc. announced?that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial. Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month. The company's Phase II COVID-19 program will also include countries outside of the United States, starting with a trial in India that is expected to begin later this year.

Negative

Vaxart, Inc Appoints James F. Cummings as Chief Medical Officer

2021-09-27 12:00:00

Vaxart, Inc. announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development. He joins Vaxart as the Company prepares to begin its Phase II clinical trials for COVID-19 with an oral tablet formulation. Dr. Cummings brings a 26-year career in the U.S. Army serving as Director of the Department of Defense's Global Emerging Infectious Surveillance and Response System (GEIS), with Biosurveillance Laboratories in 71 countries, Director of Translational Medicine & Regulated Activities for the Walter Reed Army Institute of Research (WRAIR), and Consultant to the Surgeon General for all medical research and development. Before joining Vaxart, Dr. Cummings served as President, Government and Public Health Solutions at Icon GPHS, the federal business unit of Icon PLC, a leading global Contract Research Organization (CRO), and Vice President of Clinical Development and Translational Medicine at Novavax. He joined Vaxart earlier this month.

Neutral

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2021 through Oct 06, 2021

2021-09-22 20:05:00

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2021 through Oct 06, 2021.

Neutral

Vaxart, Inc. Presents at 15th Vaccine Congress, Oct-05-2021 06:00 AM

2021-09-22 20:05:00

Vaxart, Inc. Presents at 15th Vaccine Congress, Oct-05-2021 06:00 AM. Speakers: Susan Johnson, senior scientists.

Neutral

Vaxart, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 10:40 AM

2021-09-22 17:33:00

Vaxart, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 10:40 AM. Venue: New York, United States. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Positive

Vaxart, Inc. Enters into A Lease Agreement with Britannia Pointe Grand Limited Partnership

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into a lease agreement with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership, pursuant to which the Company will have approximately 24,606 square feet of rentable space located at 170 Harbor Way, South San Francisco, California 94080. The Company is currently occupying the Harbor Way Premises pursuant to that certain sublease, dated November 13, 2020, between the Company and Vera Therapeutics, Inc., a Delaware corporation. Pursuant to the Britannia Lease Agreement, the Company will rent the Harbor Way Premises for a term of forty-two months, commencing on October 1, 2025, and expiring on March 31, 2029. The Company will pay monthly rent of $177,327.23, subject to yearly increases as specified in the Britannia Lease Agreement. On September 17, 2021, the Company entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporation. The Second Amendment amends the Lease Agreement, dated April 17, 2015, as amended by that certain First Amendment to Lease Agreement, dated September 17, 2019.

Positive

Vaxart, Inc. Enters into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporation. The Second Amendment amends the Lease Agreement, dated April 17, 2015, as amended by that certain First Amendment to Lease Agreement, dated September 17, 2019. Currently, the Company has 5,188 square feet of rentable space located at 290 Utah Avenue, South San Francisco, California 94080 (the “Existing Premises”). Effective as of April 1, 2022, the Second Amendment expands the above premises to include an additional 24,544 square feet located at 310 Utah Avenue, South San Francisco, California 94080. The Second Amendment also extends the term of this lease until March 31, 2029.

Negative

Vaxart, Inc. Announces Board Appointments

2021-09-21 20:15:00

Vaxart, Inc. announced that it has formed a Manufacturing and Quality Advisory Board. The six leaders joining Vaxart's COVID-19 Manufacturing and Quality Advisory Board are John Aunins, Ph.D.; John Carpenter, Ph.D.; Benjamin Del Tito, Ph.D.; Vijay Jethwa, Ph.D.; Robert Schiff, Ph.D.; and Clifford Siporin, Ph.D.

Negative

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

2021-09-16 00:00:00

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Negative

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million.

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 13,932,490 Price\Range: $9.574742 Transaction Features: At the Market Offering

Negative

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million.

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 13,932,490 Price\Range: $9.574742 Transaction Features: At the Market Offering

Neutral

Vaxart, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-07 20:20:00

Vaxart, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Andrei Floroiu, President and CEO, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Negative

Vaxart, Inc. Appoints Julie M. Cherrington to the Board of Directors

2021-08-23 20:23:00

On August 20, 2021, the Board of Directors of Vaxart, Inc. appointed Julie M. Cherrington, Ph.D., to serve on the Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal. The Board has determined that Dr. Cherrington meets the requirements for independence under the applicable listing standards of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. Dr. Cherrington was also appointed as a member of the Audit Committee of the Board (the “Audit Committee”). Dr. Cherrington, 63, has served since September 2020 as the Chief Executive Officer of QUE Oncology (“QUE”), a clinical stage company developing novel non-hormonal treatments for vasomotor symptoms in postmenopausal women and cancer patients receiving hormone therapy.

Negative

Vaxart, Inc. Announces the Creation of an Eight-Member Scientific and Clinical Advisory Board

2021-08-19 20:02:00

Vaxart, Inc. announced the creation of an eight-member Scientific and Clinical Advisory Board. The Advisory Board, whose first meeting occurred on July 24, 2021, is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases. The eight leaders joining Vaxart'sScientific and Clinical Advisory Board are: Ralph Baric, Ph.D., is a Distinguished Professor in the Department of Epidemiology and a Professor in the Department of Microbiology and Immunology. In addition, he is a World Technology Award Finalist and a fellow of the American Association for Microbiology. He has spent the past three decades as a world leader in the study of coronaviruses and is responsible for UNC-Chapel Hill's world leadership in coronavirus research. The Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence, pathogenesis, genetics, and cross-species transmission. He has used alphavirus vaccine vectors to develop novel candidate vaccines. Robert Belshe, M.D., directed the NIH-funded Vaccine and Treatment Evaluation Unit (VTEU) at St. Louis University for the past three decades. His clinical and laboratory research interests include the development of live attenuated respiratory virus vaccines. Recent clinical projects include the evaluation of novel vaccines for influenza, including the live attenuated influenza vaccine available for children and adults aged 2-49. Belshe coordinated 50 other academic centers to evaluate a subunit vaccine for HSV2 in women ages 18-30. More than 8,300 women participated in the trial. Stefan Gravenstein, M.D., is a professor in the departments of Medicine and Health Services Policy and Practice at Brown University's schools of medicine and public health and serves as the Director of the Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University. Gregory C. Gray, M.D., MPH, FIDSA is an infectious disease epidemiologist and Professor at Duke University with three affiliations: The Division of Infectious Diseases in Duke University's School of Medicine, the Duke Global Health Institute, and the Duke Nicholas School of the Environment. He also serves as a Professor in the Program in Emerging Infectious Diseases and the Global Health Institute at Duke-NUS Medical School, Singapore, and as a Professor of Global Health at Duke Kunshan University in China. Harry B. Greenberg, M.D., the Joseph D. Grant Professor in the School of Medicine and Associate Dean for Research at Stanford University was the lead inventor of the first-generation vaccine for rotavirus, a severe diarrheal disease that kills between 300,000 and 400,000 children each year in the developing world. Marion Pepper graduated with a bachelor's degree in Biology and English from Williams College and received her Ph.D. in Immunology in 2006 from the University of Pennsylvania. She completed postdoctoral training at the University of Minnesota and joined the Department of Immunology as an Assistant Professor in 2011, and was promoted to Associate Professor 2017. Stanley A. Plotkin, M.D., is an Emeritus Professor at the University of Pennsylvania and an Adjunct Professor at Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. In 1991, Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught, where for seven years he was the Medical and Scientific Director, based at Marnes-la-Coquette, now known as Sanofi Pasteur. George R. Siber, M.D., is an internationally recognized vaccine expert with 40 years of experience in developing numerous innovative vaccines. From 1975 to 1996, Dr. Siber served on the Faculty of Medicine at Harvard University as Assistant and Associate Professor of Medicine based at the Dana Farber Cancer Institute. Concurrently, from 1982 to 1996, Dr. Siber was Director of the Massachusetts Biologic Laboratories. Under his leadership, the laboratory developed specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis.

Neutral

Vaxart, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:40 PM

2021-08-18 15:33:00

Vaxart, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:40 PM. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Speakers: Sean N. Tucker, Senior VP & Chief Scientific Officer.

Positive

Vaxart, Inc. Announces FDA Clearance IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

2021-08-02 12:00:00

Vaxart, Inc. announced that the U.S. Food and Drug Administration has cleared Vaxart's Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. Vaxart announced in February that it had completed a Phase 1 clinical trial for its oral S+N COVID-19 vaccine.  The results from that study found that the investigational oral vaccine triggered multiple immune responses against SARS-CoV-2 antigens, while reaching primary and secondary endpoints of safety and immunogenicity, respectively.

Positive

Vaxart, Inc. Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

2021-07-29 12:22:00

Vaxart, Inc. announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. Vaxart is a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection. Vaxart's programs are based on its proprietary oral vaccine platform called VAAST. The data came from Vaxart's 12-subject Phase 1b blinded study evaluating the ability of its norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021. All seven participants who had been?previously immunized with the oral norovirus vaccine elicited?a?similar?broad range of?immune responses?to norovirus as the five subjects that had not received a prior oral vaccine dose.?? Key metrics identified in the boosting study were as follows: Serum antibody blocking titer 50,?a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. Antibody?secreting B cell (ASC) responses to norovirus VP1 measured?seven days post-boost were no different than?those in subjects receiving the vaccine for the first time. Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between subjects that had received a prior oral norovirus vaccine?and those who had not previously been vaccinated.

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.

Negative

Vaxart, Inc. Announces Auditor Changes

2021-07-20 10:05:00

On July 15, 2021, Vaxart, Inc. was notified that OUM & Co. LLP, an independent registered public accounting firm, had combined its practice with that of WithumSmith+Brown, PC and that the name of the combined practice will be WithumSmith+Brown." On July 16, 2021, OUM resigned as the auditors of the Company and the Audit Committee of the Company's Board of Directors engaged Withum to serve as the Company's new independent registered public accounting firm.

Neutral

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for Its Vapendavir Antiviral Asset

2021-07-07 12:00:00

Vaxart, Inc. announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allow Altesa to develop and commercialize Vaxart’s patented formulation of the capsid-binding VapendavirTM, a clinical stage broad spectrum antiviral. Altesa is a clinical-stage pharmaceutical company developing therapeutics addressing RNA viruses, the principal cause of global infectious disease burden. Altesa was co-founded by Dennis Liotta, PhD, Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor of Chemistry at Emory University, and George Painter, PhD, a renowned biotech entrepreneur and co-founder of Drug Innovation Ventures at Emory (DRIVE), a university-based drug discovery center established in response to the falling output and rising costs of pharmaceutical research and development. Dr. Painter is the Chief Science Officer of Altesa and Dr. Liotta serves as chairman of Altesa’s Scientific Advisory Board. Under the terms of the agreement, Altesa is granted the worldwide, exclusive right to develop, manufacture, and commercialize Vaxart’s proprietary formulation of Vapendavir. Vaxart is eligible to receive up to $130 million in development and commercial milestones, as well as tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications. Vaxart acquired Vapendavir in 2018 as part of the merger with Aviragen Therapeutics, Inc., and previously demonstrated preclinically and in clinical trials that Vapendavir is active against a broad spectrum of enteroviruses and could combat respiratory infections produced by the human rhinovirus (HRV). Vapendavir has potential applications in treating a range of infections including: epidemic hand, foot and mouth disease (HFMD) that affects millions globally, particularly in developing countries; HRV infection in chronic obstructive pulmonary disease (COPD) patients; and several illnesses affecting children, including enteroviral infections, seasonal recurrent lower respiratory tract infection (LRTI) in preschoolers, and seasonal asthma exacerbation in school-age children.

Fundamental Summary

The financials published by Vaxart for Q1 were weak and discouraging. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Correspondingly, Vaxart received a ranking of 56 and a UNDERPERFORM recommendation.

Vaxart reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.085 million compared to USD 0.506 million a year ago. Net loss was USD 25.1 million compared to USD 16.01 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.14 a year ago.

Business Description

Vaxart, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Sector Overview

Vaxart is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Vaxart's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 200.4 -9.4% 67
Liabilities 34.0 1.1% 69
Price to Book 2.8 -34.4% 47
Cash & Equivalents 123.4 -14.2% 56
Equity 166.4 -11.3% 47
EBITDA -70.5 -14.6% 51
Total Revenues 0.5 -47.2% 99
Parameter Value Change Score
Return on Equity -46.4 -2.5% 72
Net Cashflow -33.9 -300.9% 72
Capital Expenditure -5.9 -14.2% 53
Asset Turnover 0.0 -51.4% 38
Free Cashflow -0.6 -11.8% 56

* All values are TTM

The below chart reflects Vaxart's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Vaxart's peer average final assessment score stands on 61.0, Vaxart's score is 56.

  •  VXRT
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 9 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Vaxart's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Vaxart's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.

Bearish 42
Close Price 3.48
52W Low 2.7
52W High 9.8
5D MA 3.61
50D MA 3.51
200D MA 5.45
MACD -0.01
RSI 10.61
STOCH 72.22

Balance Sheet Analysis

Several numbers from Vaxart's current balance sheet were concerning, in two areas in particular: Book Value Factors and Equity. Vaxart publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 2.8, representing a -34.4% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Therefore, their book value factors earned a score of 47. Also, Vaxart management produced disappointing equity metrics this period, which stood at 166.4, representing a -11.3% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Therefore, their equity movement component earned a score of 47. At the same time, one balance sheet metric, Liabilities, was actually strongly positive. Vaxart is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 34.0, representing 1.1% change from the previous period. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 69. The company's balance sheet, Therefore, earned a score of 53.

Parameter Value Change Score
Assets 200.4 -9.4% 67
Liabilities 34.0 1.1% 69
Price to Book 2.8 -34.4% 47
Cash & Equivalents 123.4 -14.2% 56
Equity 166.4 -11.3% 47
* All values are TTM

The below chart describes Vaxart's performance as reflected on its balance sheet with respect to its peers. While Vaxart received a balance sheet score of 53, the average of its peers stands on 62.0.

  •  VXRT
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Immatics N.V. 538.7M 56 70 84 95 73 76 9 1
Agenus Inc. 520.5M 73 62 37 55 60 54 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Two metrics jump up as the most significant positive drivers of the income statement's strength in Vaxart's recent report: Revenue Efficiency and Return Factors. Vaxart did an excellent job managing its revenue efficiency this past period. Vaxart's revenue efficiency is 0.5 according to the metrics in the current filing, which represents a -47.2% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. Consequently, their revenue efficiency received a grade of 99. Also, In this filing, Vaxart reported a return on equity (ROE) ratio of -46.4, which represents a change of -2.5%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 72. That said, one metric, EBITDA, stood out as strongly negative. Vaxart's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -70.5, which represents a -14.6% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 51. Its income statement, therefore, earned a score of 68.

Parameter Value Change Score
EBITDA -70.5 -14.6% 51
Total Revenues 0.5 -47.2% 99
Return on Equity -46.4 -2.5% 72
* All values are TTM

The below chart describes Vaxart's performance as reflected on its income statement with respect to its peers. While Vaxart received a income statement score of 68 , the average of its peers stands on 67.0.

  •  VXRT
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Immatics N.V. 538.7M 37 93 53 77 9 1
Agenus Inc. 520.5M 57 83 45 74 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Vaxart appears likely to maintain its strong cash flow metrics and momentum going forward. Vaxart's management was effective in improving their net cash flow, which now sits at -33.9 and represents a -300.9% change from the previous report. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 72. Also, Vaxart's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Vaxart recorded free cash flow of -0.6, which represents a -11.8% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 56. At the same time, one critical cash flow metric, Asset Turnover, was notably weak. Vaxart's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. Vaxart recorded asset turnover of 0.0, which represents a -51.4% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. The company's asset turnover metrics seem especially problematic relative to their peers. Therefore, their asset turnover movement earned a score of 38. Their cash flow received an overall score of 65.

Parameter Value Change Score
Net Cashflow -33.9 -300.9% 72
Capital Expenditure -5.9 -14.2% 53
Asset Turnover 0.0 -51.4% 38
Free Cashflow -0.6 -11.8% 56
* All values are TTM

The below chart describes Vaxart's performance as reflected on its cash flow with respect to its peers. While Vaxart received a cash flow score of 65, the average of its peers stands on 61.0.

  •  VXRT
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Immatics N.V. 538.7M 82 95 56 99 86 9 1
Agenus Inc. 520.5M 57 43 52 77 58 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.